Only yesterday Galapagos NV GLPG (NYSE:GLPG) traded 1.96% higher at $100.96. GLPG’s 50-day average is $101.59 and its two hundred day average is $84.97. The last close is up 21.76% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 70,350 shares of the stock traded hands, down from an avg. volume of 92,500

Galapagos NV GLPG (NYSE:GLPG) had its stock price target increased to $120.00 by Stifel Nicolaus in a report issued 09/15/2017. The bumped up target suggests a potential upside of 0.19% based on the company's last stock close price.

On 8/11/2017, Stifel Nicolaus reported on Galapagos NV GLPG (NYSE:GLPG) increased the target price from $83.00 to $101.00. At the time, this indicated a possible upside of 0%.

Recent Performance Chart

With a total market value of $0, Galapagos NV GLPG has 52 week low of $57.16 and a 52 week high of $103.54 .

Also covering Galapagos NV GLPG's price target, a total of 1 analyst has issued a ratings update on Galapagos NV GLPG. The 12-month price target is $92.78 with zero analysts rating the company a strong buy, 2 firms rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokers rating the stock a sell.

More About Galapagos NV GLPG (NYSE:GLPG)

Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

The post Galapagos NV GLPG (NYSE:GLPG) target raised to $120.00, issued a report today by Stifel Nicolaus appeared first on Octafinance.